Introduction
It has been established through large-scale primary and secondary prevention studies that cholesterol-lowering therapy with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) is effective against the development of acute coronary syndromes (1) (2) (3) . The main common factor in the development of acute coronary syndromes is thrombus formation due to the rupture of coronary plaques (4) (5) (6) . Atherosclerotic plaque prone to rupture has a thin fibrous cap covering macrophages and a lipid-rich core, and this plaque can be stabilized by reducing serum total cholesterol (TC) (7) . However, the mechanism of this stabilization is still controversial.
The new statin, pitavastatin, has a strong HMG-CoA reductase inhibiting activity (8) and a relatively strong plasma TC-lowering activity as compared with other statins (9, 10) . In clinical trials involving patients with hyperlipidemia, it was confirmed to have an excellent serum cholesterollowering effect (11, 12) . We previously reported that pitavastatin suppressed the progression of atherosclerosis by reducing TC and triglyceride (TG)-rich lipoprotein in Watanabe heritable hyperlipidemic (WHHL) rabbits (13) , an animal model of heritable hyperlipidemia (14, 15) . Numerous studies have demonstrated that statins inhibit the progression of atherosclerosis and stabilize plaques in WHHL rabbits which spontaneously develop hypercholesterolemia and atherosclerosis (16) (17) (18) , but none of the authors evaluated the thickness of the fibrous cap. In this study, we evaluated plaque-stabilizing effect of pitavastatin by examining its effects on plaque components, the thickness of the fibrous cap and on monocyte chemoattractant protein (MCP)-1, matrix metalloproteinase (MMP)-3 and MMP-9.
Materials and Methods

Animals and test drug
Male homozygous WHHL rabbits (developed at Kitayama Labes, Nagano, Japan) purchased from Oriental Yeast (Tokyo, Japan) were housed in a room at 23 ± 3°C temperature and 55 ± 15 % humidity, illuminated from 7: 00 to 19: 00. Twenty-two WHHL rabbits were divided into 2 groups, control and pitavastatin, with care to avoid bias regarding the mean level of plasma TC between the two groups. Animals were fed on 150 g/day of standard chow (LRC-4; Oriental Yeast) with water ad libitum. The experiments were carried out with the approval of the Animal Ethics Committee of Kowa Company. Pitavastatin was synthesized and provided by Nissan Chemical Industries (Tokyo, Japan). Pitavastatin (equivalent to 0.5 mg/kg/day) was administered daily in the drinking water containing pitavastatin at a concentration of 0.00056 % (w/v). The duration of treatment was 16 weeks beginning at 12 weeks of age.
Measurement of plasma lipids
Blood samples were collected with EDTA (1 mg/ml) from the ear artery after overnight fasting. Plasma was separated and determined for TC and TG levels using a commercially available kit (Wako Pure Chemical Industries, Osaka, Japan). Plasma lipoprotein fractions were separated by a method previously described (13) . Very low density lipoprotein (VLDL) (d < 1.006 g/ml), intermediate density lipoprotein (IDL) (1.006 < d < 1.019 g/ml), low density lipoprotein (LDL) (1.019 < d < 1.063 g/ml) and high density lipoprotein (HDL) (1.063 < d < 1.210 g/ml) were sequentially separated by ultracentrifugation (TL-100, ultracentrifuge, TLA-100. 2 rotor; Beckman Instruments, CA, USA). These lipoproteins were determined for TC levels using a commercially available kit.
Tissue preparation
After treatment, rabbits were anesthetized with pentobarbital (30 mg/kg, iv), and perfusion-fixed with 4 % paraformaldehyde in PBS, pH7.4 (perfusion pressure 100 mmHg). The aorta from the aortic valve to the iliac bifurcation was isolated, cleaned of its surrounding fat tissue, and opened longitudinally. An image of the total aortic area was obtained with a digital camera (CAMEDIA E-10, OLYMPUS, Tokyo, Japan), and the surface lesion area was measured using an image analyzer (WinROOF Ver 3.5, Mitani Corporation, Tokyo, Japan) as previously reported (13) and expressed as a percent of the total surface area. Subsequently, the aorta was immersion-fixed overnight in 4 % paraformaldehyde.
The aorta was divided into 5 segments, ascending aorta, aortic arch, descending aorta, thoracic aorta and abdominal aorta, and the portion in each segment showing the most severe lesion shown in Fig.1 was removed, embedded in paraffin by the usual method, and sliced into 3-µm serial sections.
Histological analysis
Serial sections from each segment of the aorta were stained with hematoxylin-eosin, elastica van Gieson, Masson trichrome, sirius red and analyzed immunohistochemically. From the elastica van Gieson stained specimens, the areas of the intima and media as well as the length of the internal elastic lamina were determined, and the intima/media (I/M) area ratio and the mean thickness of the intima were calculated. The collagen area in the intima was determined in specimens stained with sirius red (Direct Red 80, Aldrich Chem, USA) (19) , and was expressed as a percentage of the total intimal area. The values in all segments were totaled to obtain a value for the entire aorta. The necrotic core was determined as the area of the extracellular vacuoles and lacunae ob- served with Masson trichrome staining (17) .
Immunohistochemical staining was performed by the ABC method (avidin-biotin peroxidase complex method) using a VESTASTAIN ABC Elite kit (PK-6100; Vector Laboratories, CA, USA). The primary antibodies used were mouse anti-rabbit macrophage (RAM-11; DAKO, CA, USA), mouse anti-human smooth muscle actin (α-SMA, 1A4; DAKO), goat anti-human MCP-1 (sc-1304; Santa Cruz Biotechnology, USA), guinea pig anti-rabbit MMP-3 (Alexis Biochemicals, USA) and mouse anti-human MMP-9 (56-2A4; Daiichi Fine Chemical, Toyama, Japan).
From the serial sections of each aortic segment, the percent positive areas of α-SMA, macrophages and collagen in the intimal area were determined, then the percentage of the total intimal area was calculated from the each segment. The average thickness of α-SMA (a / b) in the plaques in the aortic arch was calculated from the positive area (a) and the length of the internal elastic lamina beneath the plaque (b). The positive areas of MCP-1, MMP-3 and MMP-9 in the intima of the aortic arch were calculated as the percentage of total intima area by image analysis: the immunoreactive intensity of the medial was designated as the endogenous positive control. The vulnerability index (B + D / A + C) was calculated from the percent positive areas of α-SMA (A) and macrophages (B) as well as the percent areas of collagen (C) and extracellular vacuoles and lacunae (D) (20) . All the images were analyzed using an image analyzer (WinROOF Ver 3.5).
Statistical analysis
Data are presented as the mean ± SE. The statistical analysis was carried out using Student's t-test. Differences with p values less than 0.05 were regarded as statistically significant. The software used in these analyses was SAS System Release 6.12 (SAS Institute, Tokyo, Japan) and EXSAS Ver. 5.00 (Scientist Co., Tokyo, Japan).
Results
Plasma lipids
No significant differences were detected between the control and pitavastatin groups in respect of the body weight of the rabbits, and the food and water intake (data not shown). After treatment with pitavastatin, plasma TC was found to have decreased by 28.6% as compared with the control group, but the decrease in TG was not significant (Table 1) . VLDL-C, IDL-C and LDL-C were reduced by 60.0, 42.3 and 21.7%, respectively, as compared with the control group, but no effect on HDL-C was detected (Table 2) . Lipoproteins were separated by ultracentrifugation and measured for total cholesterol. Values are the mean ± SE of 11 animals. Numbers in parentheses represent the percent difference from the control group. **p < 0.01 versus the control group. Pitavastatin (0.5mg/kg/day equivalent) was given in drinking water for 16 weeks. Values are the mean ± SE of 11 animals. Numbers in parentheses represent the percent difference from the control group. **p < 0.01 versus the control group. Values are the mean ± SE of 11 animals. Numbers in parentheses represent the percent difference from the control group. **p < 0.01 versus the control group.
Extent of aortic atherosclerosis
The percent area of the atherosclerotic lesion in the entire aorta was 37.6% in the control group, while pitavastatin suppressed the progression of atherosclerosis by 38.6% as compared with the control group ( Table 3) . The I / M area ratio and average thickening of the intima in the entire aorta were calculated from the serial sections in 5 segments of the aorta. In the pitavastatin group, the I / M area ratio and average thickening of the intima in the aortic lesions were reduced by 40.5% and 40.9%, respectively, as compared with the control group (Table 3) . Figure 2 shows photomicrographs of α-SMA, collagen and macrophages, the major components of plaques, in the aortic arch of rabbits in the control and pitavastatin groups. In the pitavastatin group, the positive areas of collagen and α-SMA were increased. Macrophages were largely detected in the superficial layer in the control group but were being observed only slightly in the deeper layer in the pitavastatin group. Table 4 shows the effect of pitavastatin on the components of aortic plaques. The intimal α-SMA-positive area (mm 2 ) in the pitavastatin group did not differ from that in the control group, but the percentage of positive area examined was significantly increased in comparison with the control group (+ 91.7%). The intimal collagen area (mm 2 ) in the pitavastatin group did not differ from that in the control group, but the percentage of positive area examined was significantly in- Table 5 shows the vulnerability index for plaques in the aortic arch. Pitavastatin markedly reduced the vulnerability index from 1.96 ± 0.23 to 0.47 ± 0.12 indication that pitavastatin would be capable of stabilizing vulnerable plaques.
Histological evaluation
Pitavastatin significantly increased (+ 96.7%) the average thickening of the α-SMA-positive area in the plaques in the aortic arch as compared with the control group (Fig. 3) . Figure 4 shows photomicrographs of MCP-1, MMP-3, MMP-9 and macrophage immunostaining in the aortic arch in the control and pitavastatin groups. MCP-1, MMP-3 and MMP-9 were all detected in macrophages, smooth muscle cells and endothelial cells in the control group, and the positive areas were reduced in the pitavastatin group. Image analysis of MCP-1, MMP-3 and MMP-9 revealed that these were 39.1, 40.6 and 52.3% less in the pitavastatin group, as compared with the control group (Table 6) .
Discussion
Statins are known to halt the progression of atherosclerosis and stabilize plaque in WHHL rabbits (16) (17) (18) 20) , and the amount of collagen and smooth muscle cells in atherosclerotic plaques contributes to this stabilization. This experiment was carried out to evaluate the effects of pitavastatin on plaque components in the aorta of WHHL rabbits. Pitavastatin was administered at a dose of 0.5 mg/kg/day in drinking water for 16 weeks. In previous Values are the mean ± SE of 11 animals. Numbers in parentheses represent the percent difference from the control group. **p < 0.01 versus the control group. α-SMA, α-smooth muscle actin. Values are the mean ± SE of 11 animals. *p < 0.05, **p < 0.01 versus the control group. Values are the mean ± SE of 11 animals. Numbers in parentheses represent the percent difference from the control group. *p < 0.05, **p < 0.01 versus the control group.
experiments where the same dose was administered in drinking water, a plasma drug concentration of approximately 40 ng/ml was maintained (13) . The area under the concentration curve (AUC) from 0-24 h was 1 µg/h/ml, which was close to the Cmax attained after the administration of 2 mg to humans, so that the drug concentration in this experiment was inferred to be equivalent to the concentration attained in humans.
In this study, pitavastatin reduced TC by 28.6% at 16 weeks after treatment, with a particularly marked decrease in VLDL-C and IDL-C (Table 1, 2) . This decrease in TGrich lipoproteins such as VLDL and IDL was accompanied by a decrease in protein content (data not shown), suggesting that the decrease in particles numbers, that is, a decrease in the secretion of lipoprotein by the liver, greatly contributed to the decrease in plasma TC by pitavastatin in WHHL rabbits. In addition to improved lipids levels, treatment with pitavastatin was associated with a reduction of the lesion area, I/M area ratio and intimal thickness by about 40% each, indicating an inhibitory effect on the progression of aortic lesions (Table 3) . Furthermore, pitavastatin increased the positive area percentages of α-SMA and collagen relative to the total intimal area, and reduced that of a macrophage marker. The increase in the percentage of α-SMA and collagen by pitavastatin was not an absolute increase, but a relative increase due to a decrease in the intimal area. In addition, the decrease in the accumulation of macrophages was both absolute and relative (Table 4) .
In the control group, an accumulation of macrophages around a large necrotic core was detected in the lesions of the aortic arch, while smooth muscle cells (α-SMApositive area) were only slightly detected in the superficial layer, indicating the increased fragility of the fibrous cap (Fig. 2) . Pitavastatin treatment was associated with thickening of this fibrous cap and a significantly lower vulnerability index (Table 5 ). Though statins, including pitavastatin, are known to suppress migration and proliferation of cultured the smooth muscle cells (21) (22) (23) (24) , the smooth muscle cells in the fibrous cap were not reduced by pitavastatin, but were the same as in the control in this immunohistological examination. This was probably due to the low plasma concentration of pitavastatin (estimated to be 0.05-0.1 mmol/l), and minimal direct action of pitavastatin on smooth muscle cells.
Pitavastatin markedly reduced the accumulation of macrophages in the intima in the aortic arch. Recently, it was shown that LDL, an apoB-containing lipoprotein, binds to subendothelial extracellular matrix components, particularly proteoglycans, and remains there, and this is an important event in the early stage of atherosclerosis (25) . It is said that, among apoB-containing lipoproteins, IDL shows the highest reactivity with proteoglycans (26) . The administration of pitavastatin to WHHL rabbits reduced IDL, considered to be a more potent atherogenic lipoprotein than LDL (27) , so that the decrease in IDL-C seemed to have contributed as much as the lowering of LDL-C to the reducted in the accumulation of macrophages. Pitavastatin administration reduced the positive area of MCP-1 (Table 6) (28) .
Moreover, pitavastatin reduced the positive areas of MMP-3 and MMP-9 in the intima of the aortic arch (Fig. 3) . These findings are consistent with the effect of fluvastatin (18) and cerivastatin (29) . Statins have been reported to reduce the expression of various molecules (including MCP-1 and MMPs) independently of their cholesterol-lowering effect (30, 31) . These effects of statins are attenuated by mavalonate and its derivatives, farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) (32, 33) . Nuclear factor kappa B (NF-κB) is the key factor promoting the transcription of those molecules through small GTP-binding proteins such as Ras and Rho, which are modulated by FPP or GGPP (34) . Therefore, the inhibitory effect of statins, including pitavastatin, on MCP-1 and MMPs expression could be explained by the inhibition of NF-κB translocation into the nucleus. In addition, the reduction in the positive area of MMPs by pitavastatin seemed attributable to their decrease expression due to the suppressed accumulation of macrophages, and was considered to contribute to the reducted degradation of extracellular matrix components. Consequently, pitavastatin was considered to have suppressed the decomposition of collagen through the reducted in the production of MMPs, with the resulting increase in the percent collagen area. Statins are also known to suppress the proliferation and activation of macrophages in vitro (35, 18) . These findings suggest the possibility that statins act directly act on atherosclerotic lesions to play a role in the suppression of their progression. Therefore, pitavastatin is an excellent therapeutical drug for lipid-lowering, resulting in the suppression of atherogenesis and plaque stabilization in WHHL rabbits.
